-
New ways to develop new ways to activate T-cell anti-cancer response received $80 million in assistance
Time of Update: 2021-12-03
Recently, ATP Company announced the establishment of Marengo Therapeutics to develop new antibodies targeting T cell receptor (TCR) Vβ variants to achieve the effect of selectively activating anti-tumor T cells, and plans to promote the company’s lead drug candidates in 2022 To the clinic .
-
Click chemistry platform is expected to improve the efficacy and safety of various anti-cancer therapies
Time of Update: 2021-12-03
And further expand its click chemistry technology platform to develop therapeutic drugs that do not require intratumoral injection .
The SQ3370 developed by CAPAC is the first click chemistry-based therapy tested in humans to activate the chemotherapy drug doxorubicin at the tumor site .
-
Bioprojet company Ozawade is approved in the EU, Langyu Group develops in China
Time of Update: 2021-12-03
The European Medicines Agency (EMA) recently approved the French Bioprojet company's drug Ozawade (pitolisant, tilolisant) for the treatment of excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA) in adult patients .
-
New study says new coronavirus can infect inner ear
Time of Update: 2021-12-03
In human inner ear samples and stem cell-derived cell models, the researchers found that hair cells and Schwann cells express the proteins necessary for the new coronavirus to enter the cell-including the ACE2 receptor on the cell surface, furin and the transmembrane protease serine- 2.
-
Better efficacy than topiramate! Novartis/Amgen Aimovig head-to-head Phase 4 clinical results announced
Time of Update: 2021-12-03
Aimovig is the world's first migraine drug that targets the calcitonin-related gene peptide (CGRP) target and is jointly commercialized by Novartis and Amgen in the United States .
-
The world's first breast cancer vaccine clinical trial opens
Time of Update: 2021-12-03
CompilationFan DongdongA few days ago, researchers at the Cleveland Clinic in the United States will start a phase I vaccine trial, which may also become the first ever vaccine to prevent triple-negative breast cancer .
-
Breaking the barrier that protects tumors to help develop potential "first-in-class" therapies
Time of Update: 2021-12-03
The company plans to use the funds to develop new types of treatments that transform the tumor microenvironment and destroy cancer immune rejection .
Researchers have discovered a key molecule called DDR1 in certain types of breast cancer, which plays an important role in stabilizing tumor extracellular matrix (ECM) .
-
Too cunning!
Time of Update: 2021-12-03
According to the new study, researchers at Oregon State University used a computer vision artificial intelligence to track changes in the shape of cells during migration .
. Note: The original text has been deletedReference materials:[1] Cancer cells change shape, how theymove to invade different types of tissue, research shows.
-
Low-cost new mirror peptide can neutralize the new coronavirus
Time of Update: 2021-12-03
Science and Technology Daily News (Reporter Liu Xia) According to a recent report by the Physicist Organization Network, Canadian researchers have developed a compound that can neutralize the new coronavirus and its mutant strains-D-peptide, which can neutralize the virus and prevent its infection Human cells grown in the laboratory .
-
Takeda Pharmaceuticals debuts at CIIE with two new lung cancer products
Time of Update: 2021-12-03
In order to meet the actual clinical needs of these patients, Mobocertinib, which was introduced by Takeda for the treatment of non-small cell lung cancer with EGFR exon 20 insertion mutations, has been officially accepted by the Drug Evaluation Center of the National Medical Products Administration in China, and has been approved for priority review.
-
The team deciphering the "leprosy" code won the National Natural Science Award
Time of Update: 2021-12-03
After 36 years of dormant research in the field of leprosy prevention and treatment, Professor Zhang Furen, vice president of Shandong First Medical University, ushered in a harvest moment .
-
Treating depression, showing positive potential, hallucinogenic mushroom ingredients reach phase 2b clinical endpoint
Time of Update: 2021-12-03
A few days ago, COMPASS Pathways announced that it is developing psilocybin therapy COMP360 and has reached the primary endpoint in a Phase 2b clinical trial for the treatment of patients with refractory depression .
-
The cover of "Science" is heavy!
Time of Update: 2021-12-03
In addition to the DNA repair pathway, the researchers also found 137 genes related to longevity, which affect insulin signaling, body shape, and adaptation to the environment .
, (2021), Origins and evolution of extreme life span in Pacific Ocean rockfishes, Science, DOI: 10.
-
Innovative Mechanism of Action Novartis Leukemia Therapy Receives FDA Approval
Time of Update: 2021-12-03
The FDA has accelerated the approval of Scemblix for the treatment of Philadelphia (Ph) chromosome-positive CML patients in the chronic phase who have previously received two or more tyrosine kinase inhibitors (TKI) treatments .
Retrieved October 29, 2021, from https:// 29/2323914/0/en/FDA-approves-Novartis-Scemblix-asciminib-with-novel-mechanism-of-action-for-the-treatment-of-chronic-myeloid-leukemia.
-
What can you eat to reduce the risk of heart disease in middle-aged?
Time of Update: 2021-12-03
Spinach cannot explain Popeye’s "superhuman power", but spinach and other iron-rich foods may have other effects in real life: reducing the risk of heart disease and premature death in middle age .
-
Overcoming the shortcomings of oral Parkinson's disease therapy
Time of Update: 2021-12-03
The test results showed that compared with oral levodopa/carbidopa (levodopa/carbidopa), subcutaneous infusion of ABBV-951 for 24 hours a day significantly improved the fluctuation of motor symptoms in patients with advanced Parkinson's disease .
-
There is a difference in the time of taking the same hypoglycemic drugs
Time of Update: 2021-12-03
It turned out that Master Wang was taking a hypoglycemic drug called "Uglucose", which should be taken 30 minutes before meals .
Some diabetics also take two or more hypoglycemic drugs, which need to be taken at different times, and feel more troublesome, so they take them together .
-
How to make CAR-T therapy safer?
Time of Update: 2021-12-03
▲LiCAR-T cells shrink tumors with a high degree of specificity (picture source: reference [1])Moreover, compared with conventional CAR-T therapy, the toxic and side effects of LiCAR-T cells are much smaller.
-
Gene therapy targeting neurons in the substantia nigra is expected to improve the efficacy of levodopa in the treatment of Parkinson's disease
Time of Update: 2021-12-03
In the advanced stages of Parkinson's disease, the drug levodopa becomes less effective in treating symptoms due to the unstoppable loss of dopamine-releasing neurons .
-
Innovative therapy to reduce the level of anti-AAV neutralizing antibodies or solve the problem of repeated administration of gene therapy
Time of Update: 2021-12-03
Today, Selecta Biosciences announced that its immunomodulatory therapy ImmTOR, in a phase 1 clinical trial, can reduce the level of neutralizing antibodies produced by humans against adeno-associated virus vector 8 (AAV8) by 250 times .
